Journal article

Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists

Jacqueline K Flynn, Paula Ellenberg, Renee Duncan, Anne Ellett, Jingling Zhou, Jasminka Sterjovski, Kieran Cashin, Katharina Borm, Lachlan R Gray, Marilyn Lewis, Becky Jubb, Mike Westby, Benhur Lee, Sharon R Lewin, Melissa Churchill, Michael Roche, Paul R Gorry

AIDS Research and Human Retroviruses | MARY ANN LIEBERT, INC | Published : 2017

Grants

Awarded by Australian National Health and Medical Research Council (NHMRC)


Funding Acknowledgements

This study was supported by a grant from the Australian National Health and Medical Research Council (NHMRC) to PRG (1059394). We thank J. Sodroski for providing the pSVIII-Env plasmid, pCMV Delta P1 Delta envpA and pHIV-1Luc plasmids, N. Shimizu and H. Hoshino for permission to use NP2-CD4/CCR5 cells, and D. Mosier and R. Nedellec for supplying the NP2-CD4/CCR5 cells. We also thank J. Demarest and F. Drummond from ViiV Healthcare for providing MVC, for permission to use MOTIVATE trial clinical data and Env amplicons derived from clinical samples, and for helpful comments on the article. TAK-779 was obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH.